Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +8.51% Return-on-Tangible-Asset is -64.62% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, Adlai Nortye ranks worse than 64.83% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Adlai Nortye's annualizedNet Income for the quarter that ended in Dec. 2025 was $-34.39 Mil. Adlai Nortye's average total tangible assets for the quarter that ended in Dec. 2025 was $53.22 Mil. Therefore, Adlai Nortye's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -64.62%.
The historical rank and industry rank for Adlai Nortye's Return-on-Tangible-Asset or its related term are showing as below:
ANL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -107.81 Med: -57.61 Max: -43.07
Current: -59.99
During the past 5 years, Adlai Nortye's highest Return-on-Tangible-Asset was -43.07%. The lowest was -107.81%. And the median was -57.61%.
ANL's Return-on-Tangible-Asset is ranked worse than 64.83% of 1416
companies
in the Biotechnology industry
Industry Median: -35.915
vs ANL: -59.99
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Adlai Nortye Return-on-Tangible-Asset Related Terms
Adlai Nortye Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs OMER, PRME, DNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Adlai Nortye's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -64.62% mean?
Adlai Nortye (ANL) has a Return-on-Tangible-Asset of -64.62% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #918 out of 1416 companies in the Biotechnology industry, placing it in the top 64.8%.
Is Adlai Nortye's Return-on-Tangible-Asset too high?
Adlai Nortye's current Return-on-Tangible-Asset is -64.62%. Based on the distribution chart, Adlai Nortye ranks #918 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint.
How does Adlai Nortye's Return-on-Tangible-Asset compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #918 out of 1416 companies for Return-on-Tangible-Asset. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Return-on-Tangible-Asset is -64.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Return-on-Tangible-Asset of -64.62%. The current Return-on-Tangible-Asset is -64.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Return-on-Tangible-Asset is -64.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
